Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Nightstar Therapeutics plc (NITE) Announces Positive Proof of Concept NSR-RPGR Data
September 24, 2018 6:39 AM EDTOn Saturday, Nightstar Therapeutics plc (NASDAQ: NITE) announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress.
We initiated this study last year, with the anticipation of demonstrating safety and stabilization of disease with NSR-RPGR, our codon-optimized gene therapy for XLRP, said Tuyen Ong, M.D., chief development officer of Nightstar. Based on the preliminary findings of improved visual function as measured by microperimetry, we have established early proof of concept in... More
Nightstar Therapeutics (NITE) PT Raised to $41 at BMO Capital
September 24, 2018 5:42 AM EDTBMO Capital analyst Matthew Luchini raised the price target on Nightstar Therapeutics (NASDAQ: NITE) to $41.00 (from $30.00) while maintaining a Outperform rating.
... More